Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Myocarditis IV: Nursing Management

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations.

Blood reviews·2019

Same author

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.

Blood cancer journal·2016

Same author

Antiphospholipid Antibodies and Associated Clinical Manifestations.

Hematology (Amsterdam, Netherlands)·2016

Same author

The Management of Essential Thrombocythaemia.

Hematology (Amsterdam, Netherlands)·2016

Same author

The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances.

Blood reviews·2016

Same author

PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status.

Thrombosis research·2016

Search research articles

Related Experiment Video

Updated: May 27, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

How to manage essential thrombocythemia.

¹Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy. gfinazzi@ospedaliriuniti.bergamo.it

|November 5, 2011

Summary

Essential thrombocytemia diagnosis relies on WHO criteria. A risk-oriented approach guides treatment to minimize complications and toxicity, prioritizing hydroxyurea for high-risk patients.

Area of Science:

Hematology
Oncology
Molecular Diagnostics

Background:

Essential thrombocytemia diagnosis utilizes updated World Health Organization criteria.
Morbidity and mortality in essential thrombocytemia are primarily linked to thrombosis and bleeding.
Therapeutic strategies aim to mitigate vascular complications while managing treatment-related toxicity.

Purpose of the Study:

To outline a risk-oriented therapeutic strategy for essential thrombocytemia.
To identify established and novel risk factors for cardiovascular events.
To guide treatment decisions based on patient risk stratification.

Main Methods:

Diagnosis based on hematological, morphological, and molecular criteria.
Risk stratification using age, prior thrombosis, leukocytosis, and JAK2V617F status.

Related Experiment Videos

Last Updated: May 27, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Treatment selection including hydroxyurea, interferon alpha, and anagrelide.

Main Results:

Older age and prior thrombosis are established cardiovascular event predictors.
Leukocytosis and JAK2V617F mutation status are emerging prognostic factors.
Asymptomatic, low-risk patients require no intervention; high-risk patients are treated with hydroxyurea.

Conclusions:

A risk-oriented approach is crucial for managing essential thrombocytemia.
Hydroxyurea is the first-line treatment for high-risk patients.
Pregnancy management involves risk stratification with aspirin and low-molecular-weight heparin.